|
Regulatory Affairs Journal (RAJ) Pharma is the definitive global regulatory reference source for the pharmaceutical industry. Required reading for regulatory affairs professionals, RAJ is the most respected publication in the market. When selling your products and services, the pages of RAJ deliver your prospects in an appropriate editorial environment, engaging them in the workplace.
To discuss the full scope of the digital and print advertising solutions we offer, please contact our team on: +44 (0)20 3377 3170, regulatory@informa.com
Request a media pack
Readership Facts
RAJ Pharma has over 3700 readers worldwide, the majority being based in leading pharmaceutical and biotech companies.
|
Activity of Company
|
%
|
|
Pharmaceutical & Biotechnology
|
73%
|
|
Bulk pharmaceutical manufacturers
|
7%
|
|
Legal/Government/Association
|
6%
|
|
CRO's
|
4%
|
|
Consultants
|
4%
|
|
Other
|
2%
|
|
Geographic Breakdown
|
%
|
|
Europe
|
56%
|
|
UK
|
21%
|
|
North America and Latin America
|
12%
|
|
Asia & Africa
|
7%
|
|
ROW
|
4%
|
|
Responsibility of Readers
|
%
|
Regulatory Affairs/Quality Assurance/
Compliance Manager/Lawyer
|
44%
|
|
Administrator/Assistant
|
13%
|
|
CEO/ Director/ Head/MD/President/VP
|
39%
|
|
Other
|
4%
|
To discuss the full scope of the digital and print advertising solutions we offer, please contact our team on: +44 (0)20 3377 3170,regulatory@informa.com
|
Request a media pack
Readership facts
Activity of company
Geographic breakdown
Responsibility of readers
RAJ enables companies to:
|
|
Make faster, better strategic decisions
|
|
|
Accelerate regulatory application processes
|
|
|
Achieve faster time to market for drugs
|
|
|
Minimise regulatory compliance costs
|
|
|
Maximise market share in existing and new sectors
|
|
